{"name":"Alexza Pharmaceuticals, Inc.","slug":"alexza-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Alexza Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research and development of innovative drug delivery systems, particularly in the area of inhalation technology. The company has a pipeline of six drugs in various stages of development, with a strong emphasis on pain management and psychiatric disorders.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5026000,"revenueGrowth":646.8,"grossMargin":0,"rdSpend":11716000,"netIncome":-21310000,"cash":14731000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"009-A0","genericName":"009-A0","slug":"009-a0","indication":"Other","status":"phase_1"},{"name":"009-A1","genericName":"009-A1","slug":"009-a1","indication":"Other","status":"phase_1"},{"name":"009-A2","genericName":"009-A2","slug":"009-a2","indication":"Other","status":"phase_1"},{"name":"009-A3","genericName":"009-A3","slug":"009-a3","indication":"Other","status":"phase_1"},{"name":"Inhaled loxapine 10 mg","genericName":"Inhaled loxapine 10 mg","slug":"inhaled-loxapine-10-mg","indication":"Other","status":"marketed"},{"name":"Inhaled prochlorperazine 5 mg","genericName":"Inhaled prochlorperazine 5 mg","slug":"inhaled-prochlorperazine-5-mg","indication":"Other","status":"phase_1"},{"name":"Intravenous Fentanyl 25 mcg","genericName":"Intravenous Fentanyl 25 mcg","slug":"intravenous-fentanyl-25-mcg","indication":"Other","status":"phase_1"},{"name":"Placebo IM","genericName":"Placebo IM","slug":"placebo-im","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"IV doxapram","genericName":"IV doxapram","slug":"iv-doxapram","indication":"Respiratory depression","status":"phase_2"},{"name":"C=Inhaled Alprazolam 1 m","genericName":"C=Inhaled Alprazolam 1 m","slug":"c-inhaled-alprazolam-1-m","indication":"Anxiety disorders","status":"phase_2"},{"name":"Inhaled Loxapine","genericName":"Inhaled Loxapine","slug":"inhaled-loxapine","indication":"Acute agitation associated with schizophrenia or bipolar disorder","status":"phase_3"}]}],"pipeline":[{"name":"009-A0","genericName":"009-A0","slug":"009-a0","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IV doxapram","genericName":"IV doxapram","slug":"iv-doxapram","phase":"phase_2","mechanism":"Stimulates the central nervous system to increase respiratory rate","indications":["Respiratory depression"],"catalyst":""},{"name":"009-A1","genericName":"009-A1","slug":"009-a1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"009-A2","genericName":"009-A2","slug":"009-a2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"009-A3","genericName":"009-A3","slug":"009-a3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"C=Inhaled Alprazolam 1 m","genericName":"C=Inhaled Alprazolam 1 m","slug":"c-inhaled-alprazolam-1-m","phase":"phase_2","mechanism":"Alprazolam acts as a positive allosteric modulator of the GABAA receptor, enhancing the inhibitory effects of GABA in the central nervous system.","indications":["Anxiety disorders","Panic disorders"],"catalyst":""},{"name":"Inhaled Loxapine","genericName":"Inhaled Loxapine","slug":"inhaled-loxapine","phase":"phase_3","mechanism":"Inhaled loxapine is a rapid-acting antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce acute agitation.","indications":["Acute agitation associated with schizophrenia or bipolar disorder"],"catalyst":""},{"name":"Inhaled loxapine 10 mg","genericName":"Inhaled loxapine 10 mg","slug":"inhaled-loxapine-10-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inhaled prochlorperazine 5 mg","genericName":"Inhaled prochlorperazine 5 mg","slug":"inhaled-prochlorperazine-5-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Intravenous Fentanyl 25 mcg","genericName":"Intravenous Fentanyl 25 mcg","slug":"intravenous-fentanyl-25-mcg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo IM","genericName":"Placebo IM","slug":"placebo-im","phase":"marketed","mechanism":"Placebo IM is an inert substance administered by intramuscular injection that produces no pharmacological effect.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxNcEd6Rkt1MDFqcjhKb3lGcFJKT0dKOUFfcS1aOUtKTEtXMzB0Mzd3dGF1NGRlTExhMGQ4dGFVMEhFaDhLZ1RiSEpMb0VqWGZtVmFXM1ZQUHF2cnQ0UEVkT0ExeEticlFxaTA5NDZYY1BWQ3B5cWJPU2hsWjBwZGthR0plc18wNUhJNzA5enpJOTRTUURWV3pvclpwbVdJcnMxR0x4WVdmY21MQktTYTdDdFBWYmxqMkR0T2RFNEotZGc4SUxGNG9PNVRIblpvTWJJSjNGTU1xX1BQT0YxeFRSNENReGpUeTR1WDZLZm1EN2MxM2JrYlJXeHUzU3BQSFV6MVBrSEZ3MnhYLUNFVXlSLUxsUG0wMWlnVDdmcC14YUVMNjZFMmhpUWMzUjlwYWJxbTVuSF9qX215VnFPdGNpUjZHTll3MTI1UTBVNHAyVkQ0WXVpRHdnVS1tVGtUbndRU0NF?oc=5","date":"2025-12-11","type":"deal","source":"PR Newswire","summary":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights - PR N","headline":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Ex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNMDhJQW56MmN4YUVZenB4MmRmT1RWM205VThJcktnQlFzX2swNVNvSWYxeUE0RkphY0NkdkZtNHZPMUt6ekdMSDU4QmJwbWF3U3hiRXpkS3M5WkF1WEpyNV9CTlFyM3lpTER1OTdfZXhmdlJpLUJQUm5JR3d4Tl83TWpSMjk0bWxQRWZ2eHhLelRrQTJhUGYyOWRlZXJWdw?oc=5","date":"2016-06-21","type":"deal","source":"PR Newswire","summary":"Alexza Pharmaceuticals Acquired by Ferrer - PR Newswire","headline":"Alexza Pharmaceuticals Acquired by Ferrer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBxMDREVmw0VThUcVQ5WkpuZXRBYUxubXFtS1g1cm9JTnJzWFl2cVNFdG8zTWN0MTFaNTd6aGxUMEFhSXVwZU9CS09pUHcwNkNXd2NScU96c0d0Z0FRWWt1NlI0N3JrM2tpNEdsd1N1MjNXZnhGTWhfYUVWYy1Idw?oc=5","date":"2016-05-10","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Ferrer to Acquire Alexza Pharmaceuticals - Genetic Engineering and Biotechnology News","headline":"Ferrer to Acquire Alexza Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQS1ZqSzZuSDJoc2Q5ZjE0OW5NU2s2OUVuSUJSbzB5SHRndU92dDM2cFdGdFQyTUlqMnBTT1Vna01IY2d4WmoyYVJYWnp0TElESE1uMzRPNjYzTkQ2SEI3cEVWcWJ4YlBOMGlKRDd6ZVlMT2FJRDdhZ1VadlBJVU8xbEp6ME5sVmtLaTI3UDRibHRZNWZ6bkMtLVNMcnJ0SUpIQW9qWlBB?oc=5","date":"2016-05-10","type":"deal","source":"PR Newswire","summary":"Alexza Pharmaceuticals to be Acquired by Ferrer - PR Newswire","headline":"Alexza Pharmaceuticals to be Acquired by Ferrer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOclNITDIxY1VzS3dyZ1ZiLWhlcTFhMkpQMWsweDNqU045ek00d2hXMHAydVRlb3V3LTc0R0FLaUtxRXgwajk2VEEzZUp1YTNFenlXRHlnMmo2Mm9UUUF4cVgwLVBFblQ3Y0xFdThaemptd2RFVEhDYnFMeHBtb1Jqd3dfSlhRYlB1ZzhsRDQ1TjRmd2FkN3VjMlRRR3JSaVlxOHZpTTJXM3l1SGE5dDJ0aTVXVWszUQ?oc=5","date":"2014-03-04","type":"pipeline","source":"Fierce Pharma","summary":"Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals - Fierce Pharma","headline":"Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_1":6,"phase_2":2,"phase_3":1,"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5026000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":5026000,"period":"2015-12-31"},{"value":673000,"period":"2015-12-31"},{"value":1773000,"period":"2015-09-30"},{"value":1875000,"period":"2015-06-30"},{"value":705000,"period":"2015-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11716000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-21310000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":14731000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}